Genetix Biotherapeutics Analysis: $1.1B Raised
What is Genetix Biotherapeutics?
Genetix Biotherapeutics focuses on delivering curative genetic therapies for patients with sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy. The company utilizes a proprietary approach involving the modification of a patient's own blood stem cells to treat the underlying causes of these diseases. Their therapies have been developed over 30 years and are approved under FDA safety standards.
Location
Somerville, Massachusetts, United States
Employees
201-500
Founded
1992
Funding Status
Series A
Product Features & Capabilities
- LYFGENIA
- ZYNTEGLO
- SKYSONA
- Patient support services
- Clinical trials monitoring
Use Cases
Treat sickle cell disease to alleviate pain crises; Provide beta-thalassemia treatment to reduce transfusion needs; Offer CALD therapy to slow brain damage progression; Support patients with personalized treatment journey assistance; Monitor long-term safety in clinical trial participants
Other Considerations
Transitioned to a privately held company in 2025; Newly appointed leadership team with extensive biotech experience; Strong focus on commercial execution and patient access
See something that needs updating? Suggest edits to this profile.